Flow cytometric analysis of DNA content in colorectal carcinoma.
Over the past decade, flow cytometric DNA analysis has been employed by a number of investigators in an attempt to further define patient prognosis beyond classic pathologic staging. The results of these studies taken independently have been confusing; however, their cumulative effect suggests that flow cytometry is a useful prognostic indicator and can be used to further delineate prognosis within a specific pathologic stage. DNA nondiploid tumors are more likely to recur than diploid tumors, and patients with DNA nondiploid tumors have a poorer five-year survival than patients with DNA diploid tumors. There appears to be a weak relationship between advanced pathologic stage and DNA aneuploid tumors, although there is no clear and consistent relationship between tumor ploidy and histology. Therefore, all patients with colorectal tumors should undergo DNA ploidy analysis. Patients with DNA nondiploid tumors should be treated for biologically more aggressive disease independent of other prognostic variables. Ploidy status should be employed as a variable by which to randomize patients to both primary treatment schemes and adjuvant therapies in clinical trials.